Comparing the current results to its competitors, Quoin Pharmaceuticals Ltd reported Revenue decrease in the 2 quarter 2026 year on year by -73.6 %, despite the revenue increase by the most of its competitors of 15.47 %, recorded in the same quarter.
Quoin Pharmaceuticals Ltd 's Comment on Competition and Industry Peers
The clinical biotechnology industry includes biotechnology and pharmaceutical companies, academic institutions, and public and private research organizations. These entities conduct research, discovery, and development of new medicines and treatments for substance use, pursue patent protection and licensing revenues, and compete for skilled talent. Some competitors have greater size and funding. The company may face challenges in effectively competing with these entities or keeping pace with technological advancements and market conditions.
November 5, 2024
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a noteworthy player in the realm of clinical-stage specialty pharmaceuticals, has made significant strides in its commitment to developing cutting-edge treatments for rare and orphan diseases. As announced from their headquarters in Ashburn, Virginia on November 5, 2024, the company has commenced clinical testing of its lead product, QRX003, in a young child diagnosed with Netherton Syndrome (NS) a rare genetic condition characterized by a triad of symptoms, including congenital ichthyosis, atopic diathesis, and hair abnormalities. Currently, there are no approved treatments or cures available for this debilitating disease.In a landmark development for Quoin Pharmac...
June 25, 2024
ASHBURN, Va., June 25, 2024 In a significant move underscoring its commitment to the rare disease community, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company focused on developing treatments for rare and orphan diseases, announces its role as a Bronze Sponsor for the Foundation for Ichthyosis and Related Skin Types (FIRST) 2024 national conference. The event will take place in Albuquerque, New Mexico from June 28-30, 2024.The FIRST national conference represents a critical convergence point for patients, families, researchers, and healthcare professionals dedicated to understanding and managing ichthyosis and related skin types. As a debilitating genetic disorder...
June 12, 2024
Quoin Pharmaceuticals recently announced the signing of a significant research agreement with University College Cork (UCC) in Ireland. This exciting collaboration aims to focus on the development of unique topical rapamycin (sirolimus) formulations as potential treatments for a range of rare and orphan diseases. Rapamycin, a potent immunosuppressive drug originally derived from bacteria found on Easter Island, has already demonstrated its efficacy in various medical applications. However, its utilization as a topical treatment for rare diseases remains largely unexplored. This research agreement between Quoin Pharmaceuticals and UCC seeks to bridge this gap and uncover new possibilities in saving lives and ...
March 4, 2024
FDA Grants Quoin Pharmaceuticals Clearance to Include Teen Patients in Ongoing Netherton Syndrome Clinical Trials: Potentially Expediting Recruitment and Enhancing Data AnalysisIn a significant development, Quoin Pharmaceuticals has received FDA clearance to enroll teenage patients in their ongoing clinical studies for the treatment of Netherton Syndrome. This regulatory approval is expected to expand the pool of eligible participants, potentially accelerating the recruitment process and leading to a more comprehensive and robust dataset.Netherton Syndrome is a rare and debilitating genetic skin disorder that primarily affects infants and young children. Characterized by severe skin inflammation, impaired sk...
Publicly Traded Peers of Quoin Pharmaceuticals Ltd
Capricor Therapeutics inc Share Performance
+33.47%
30 Days
Capricor Therapeutics inc
Profile
Capricor Therapeutics Inc's business model revolves around developing innovative regenerative medicine therapies for the treatment of diseases that have unmet medical needs.
International Stem Cell Corporation Share Performance
+142.86%
One Year
International Stem Cell Corporation
Profile
International Stem Cell Corporation is a biotechnology company that focuses on developing and commercializing stem cell-based therapeutic products. They utilize their unique technology to derive unlimited amounts of pluripotent stem cells, enabling them to create therapeutics for various medical conditions.
Longeveron Inc's business model involves the development and commercialization of regenerative medicine products using mesenchymal stem cells for various medical conditions.
Sources:
Quoin Pharmaceuticals Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Quoin Pharmaceuticals Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
